Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for NAFLD with Advanced Fibrosis in T2DM
NCT05751720Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirzepatide in non-alcoholic fatty liver disease (NAFLD). Primary endpoints: Change in liver stiffness at 12 months and Change in Liver fat quantification at 12 months. Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05751720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751720.